Targeting CXCR4 together with other membrane molecules involved in the attachment of AML (stem) cells to the BM niche may be an efficient strategy to release AML LSCs and enhance their sensitivity to therapy. This evidence concerns the gene CXCR4 and acute myeloid leukemia.